Renalytix Plc
RNLX · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.02 | 0.16 | 0.03 |
| FCF Yield | -34.71% | -45.16% | -12.18% | -43.08% |
| EV / EBITDA | -4.56 | -3.88 | -7.36 | -2.58 |
| Quality | ||||
| ROIC | 133.55% | -811.31% | 380.17% | -1,290.86% |
| Gross Margin | 19.16% | 6.14% | -12.34% | 32.30% |
| Cash Conversion Ratio | 0.81 | 1.11 | 0.63 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.05% | -8.32% | -5.25% | -0.11% |
| Free Cash Flow Growth | 50.99% | -60.88% | 38.57% | 16.68% |
| Safety | ||||
| Net Debt / EBITDA | -1.82 | -0.71 | -0.78 | -0.35 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.94 |
| Cash Conversion Cycle | -1,037.94 | -426.76 | -674.72 | -258.09 |